Regeneron Gets $407 Million in Damages From Amgen in Antitrust Drug Lawsuit

Published: 2025-05-15 15:34:07 ET AMGN

Published on 05/15/2025 at 15:34

By Katherine Hamilton

Regeneron Pharmaceuticals won $406.8 million in damages for a lawsuit claiming Amgen violated antitrust and tort laws.

A jury in a Delaware court found that Amgen violated certain laws, and gave Regeneron $135.6 million in compensatory damages and $271.2 million in punitive damages.

Regeneron had alleged in a lawsuit that Amgen was purposely excluding Regeneron's anti-inflammatory cholesterol drug Praluent from the marketplace.

The pharmaceutical company claimed Amgen bundled anti-inflammatory drugs Enbrel and Otezla to convince pharmacy benefit managers to select Repatha as the exclusive PCSK9 category product over Praluent. Amgen also threatened to withhold rebates to the managers unless they chose Repatha over Praluent, the company alleged.

Write to Katherine Hamilton at [email protected]

(END) Dow Jones Newswires

05-15-25 1533ET